Drug developer Xoma announced that it has licensed technology to Pfizer that can be used to screen and make antibody products, the Associated Press reported.
Xoma said it will license the technology for an upfront payment of $30 million, along with future royalty and milestone payments.
Xoma also licenses the technology to companies including Merck, Centocor and Alexion Pharmaceuticals. Xoma receives royalties from Genentech for its macular degeneration drug Lucentis because that drug uses its bacterial cell expression technology.
